A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.

Yara RodríguezKenji UnnoMihai I TruicaZachary R ChalmersYoung A YooRajita VatapalliVinay Sagar Jindan YuBarbara LysyMaha HussainHuiying HanSarki A Abdulkadir

Published in: Cancer research (2022)

PRRX2 mediates enzalutamide resistance via activation of the E2F and BCL2 pathways, which can be targeted with CDK4/6 and BCL2 inhibitors to reverse resistance.

Keyphrases

prostate cancer
genome wide
radical prostatectomy
dna methylation
crispr cas
genome editing
gene expression
cell cycle
copy number
cell proliferation
single cell